Novavax, Inc. (NVAX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$9.85-3.34%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Novavax aims for $230M-$270M revenue in 2026, showing growth potential. The company secured a licensing deal with Pfizer for Matrix-M, supporting future revenue. Costs are targeted at $325M for R&D and SG&A, indicating expense control. Recent earnings beats show some operational improvement.
Revenue growth is weak with analysts expecting a 43% decline next year. The company remains loss-making with negative EPS forecasts. Loss of partnership with Sanofi and recent impairments raise strategic risks.
The price is about 27% below our fair value of $12.9, reflecting stretched expectations with analysts forecasting a 43% revenue decline. Our view is more optimistic on revenue recovery and licensing benefits.
Breaks if: Combined R&D and SG&A expenses exceed $325M in FY26
Breaks if: Loss or termination of Matrix-M licensing agreement with Pfizer
Revenue falls below $230M in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state is intact, with recent earnings beats suggesting some momentum, though the overall execution quality remains fragile.
The market seems to price NVAX as relatively cheap compared to peers, but with a significant expectations gap. This indicates that investors may have low confidence in future earnings performance despite the recent positive results.
Management aims to achieve revenue of $235M-$275M for 2026, but recent quarterly revenue has shown fluctuations. The company is also focused on managing R&D and SG&A expenses effectively, which is crucial for its financial health.
The long-term thesis hinges on management's ability to meet revenue targets without cutting guidance, as well as external factors like the performance of sector bellwethers and broader economic conditions impacting healthcare stocks.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the outlook. The company raised its revenue target for 2026 to $230 million to $270 million. This positive news aligns with improved investor sentiment in the vaccine sector. Stocks in this sector are rising due to positive trial results from peers.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, NVAX's performance will depend on its execution and the overall healthcare sector dynamics. Not investment advice.